Objective: To investigate the effect of secretory IgA combined with conventional anti-infectious drugs on inflammatory response and immune response in children with upper respiratory tract infection. Methods: A total ...Objective: To investigate the effect of secretory IgA combined with conventional anti-infectious drugs on inflammatory response and immune response in children with upper respiratory tract infection. Methods: A total of 130 children with upper respiratory tract infection who were treated in the hospital between February 2016 and February 2017 were divided into control group and secretory IgA group by random number table method, each group with 65 cases. Control group received routine anti-infectious drug treatment, and secretory IgA group received the secretory IgA combined with conventional anti-infectious drug treatment, which lasted for 1 week. The differences in serum levels of routine inflammatory factors, fat inflammatory factors and immunoglobulin were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of normal inflammatory factors, fat inflammatory factors and immunoglobulin between the two groups before treatment. After 1 week of treatment, serum conventional inflammatory factors CRP, IL-1 and IL-8 levels of secretory IgA group were lower than those of control group;serum fat inflammatory factors SAA and Chemerin levels were lower than those of control group whereas Leptin level was higher than that of control group;serum immunoglobulin IgA, IgG and IgM contents were higher than those of control group. Conclusion: The secretory IgA combined with conventional anti-infectious drugs can effectively inhibit the systemic inflammatory response and enhance the humoral immune response in children with upper respiratory tract infection.展开更多
Objective:To investigate the effects of secretory IgA on the inflammatory response and immune function indicators in children with upper respiratory tract infection.Methods:A total of 80 children with recurrent upper ...Objective:To investigate the effects of secretory IgA on the inflammatory response and immune function indicators in children with upper respiratory tract infection.Methods:A total of 80 children with recurrent upper respiratory tract infection who received treatment in our hospital between September 2017 and September 2018 were retrospectively analyzed and divided into the control group(n=43)receiving conventional anti-infective drug therapy and the sIgA group(n=37)receiving secretory IgA combined with conventional anti-infective drug therapy according to the treatment regimen.The differences in serum contents of inflammatory cytokines and immunoglobulins as well as peripheral blood levels of Th1/Th2 immune response indexes were compared between the two groups before treatment and after 7 days of treatment.Results:Before treatment,there were no significant differences in serum contents of inflammatory cytokines and immunoglobulins or peripheral blood levels of Th1/Th2 immune response indexes between the two groups.After 7 days of treatment,serum inflammatory cytokines tumor necrosis factor-α,interleukin-2 and interleukin-18 contents of the sIgA group were lower than those of the control group;serum immunoglobulin IgE content was lower than that of the control group,while IgG2 and IgG4 contents were higher than those of the control group;peripheral blood Th1 cell distribution proportion and Th1/Th2 ratio were higher than those of the control group,while Th2 cell distribution proportion was lower than that of the control group.Conclusion:Conventional anti-infective drugs combined with secretory IgA can further inhibit the inflammatory response and balance the immune response in children with recurrent upper respiratory tract infections.展开更多
Recently,new findings have been clarified concerning both pathogenesis and treatment of IgA nephritis.The four hits theory has been confirmed but several genetic wide association studies have allowed finding several g...Recently,new findings have been clarified concerning both pathogenesis and treatment of IgA nephritis.The four hits theory has been confirmed but several genetic wide association studies have allowed finding several genes connected with the pathogenesis of the disease.All these new genes apply to each of the four hits.Additionally,new discoveries concerning the microbiota and its connection with immune system and IgA generation have allowed finding out the role of the mucosa in IgA nephropathy pathogenesis.The IgA treatment is also changed included the future possibilities.The treatment of the chronic kidney disease,associated with the nephropathy,is mandatory,since the beginning of the disease.The classical immunosuppressive agents have poor effect.The corticosteroids remain an important cornerstone in any phase of the disease.More effect is related to the treatment of B cells and plasma cells.In particular,in very recent studies have been documented the efficacy of anti B cell-activating factor and anti A proliferation-inducing ligand agents.Most of these studies are to date in phase II/III.Finally,new agents targeting complement are arising.These agents also are still in randomized trials and act principally in hit 4 where the immunocomplexes in the mesangium activate the different pathways of the complement cascade.展开更多
原发性IgA肾病(IgA nephropathy,IgAN)是一种常见的肾小球疾病,是导致肾功能衰竭的重要原因,主要见于青年人和儿童。在过去的几十年里,糖皮质激素疗法一直备受争议。IgA肾病激素治疗评估的全球研究(the therapeutic effects of steroids...原发性IgA肾病(IgA nephropathy,IgAN)是一种常见的肾小球疾病,是导致肾功能衰竭的重要原因,主要见于青年人和儿童。在过去的几十年里,糖皮质激素疗法一直备受争议。IgA肾病激素治疗评估的全球研究(the therapeutic effects of steroids in IgA nephropathy global,TESTING)始于2012年,是一项国际性、多中心、双盲、随机、安慰剂对照试验,旨在评估在优化支持治疗条件下口服甲泼尼龙治疗进展风险高的IgAN患者的安全性和长期疗效。经过十年的努力,这项研究的成功完成表明,6~9个月的口服甲泼尼龙是保护IgAN高危患者肾功能的有效方案,但也显示出安全问题。TESTING研究发现,与全剂量甲泼尼龙方案相比,减少剂量的甲泼尼龙方案是有益的,且剂量的减少有助于提高甲泼尼龙的使用安全性。总的来说,TESTING研究提供了更多关于IgAN中糖皮质激素治疗剂量和安全性的数据。TESTING研究结果给患有IgAN的患儿提供了重要的启示。随着对IgAN发病机制的深入了解,正在进行的新治疗方案的研究将有助于进一步优化IgAN治疗的获益-风险比。展开更多
基金Natural Science Foundation of China No:81171365.
文摘Objective: To investigate the effect of secretory IgA combined with conventional anti-infectious drugs on inflammatory response and immune response in children with upper respiratory tract infection. Methods: A total of 130 children with upper respiratory tract infection who were treated in the hospital between February 2016 and February 2017 were divided into control group and secretory IgA group by random number table method, each group with 65 cases. Control group received routine anti-infectious drug treatment, and secretory IgA group received the secretory IgA combined with conventional anti-infectious drug treatment, which lasted for 1 week. The differences in serum levels of routine inflammatory factors, fat inflammatory factors and immunoglobulin were compared between the two groups before and after treatment. Results: There was no statistically significant difference in serum levels of normal inflammatory factors, fat inflammatory factors and immunoglobulin between the two groups before treatment. After 1 week of treatment, serum conventional inflammatory factors CRP, IL-1 and IL-8 levels of secretory IgA group were lower than those of control group;serum fat inflammatory factors SAA and Chemerin levels were lower than those of control group whereas Leptin level was higher than that of control group;serum immunoglobulin IgA, IgG and IgM contents were higher than those of control group. Conclusion: The secretory IgA combined with conventional anti-infectious drugs can effectively inhibit the systemic inflammatory response and enhance the humoral immune response in children with upper respiratory tract infection.
基金This study was supported by the Science and Technology Key Project(Grant No:2017ks-04).
文摘Objective:To investigate the effects of secretory IgA on the inflammatory response and immune function indicators in children with upper respiratory tract infection.Methods:A total of 80 children with recurrent upper respiratory tract infection who received treatment in our hospital between September 2017 and September 2018 were retrospectively analyzed and divided into the control group(n=43)receiving conventional anti-infective drug therapy and the sIgA group(n=37)receiving secretory IgA combined with conventional anti-infective drug therapy according to the treatment regimen.The differences in serum contents of inflammatory cytokines and immunoglobulins as well as peripheral blood levels of Th1/Th2 immune response indexes were compared between the two groups before treatment and after 7 days of treatment.Results:Before treatment,there were no significant differences in serum contents of inflammatory cytokines and immunoglobulins or peripheral blood levels of Th1/Th2 immune response indexes between the two groups.After 7 days of treatment,serum inflammatory cytokines tumor necrosis factor-α,interleukin-2 and interleukin-18 contents of the sIgA group were lower than those of the control group;serum immunoglobulin IgE content was lower than that of the control group,while IgG2 and IgG4 contents were higher than those of the control group;peripheral blood Th1 cell distribution proportion and Th1/Th2 ratio were higher than those of the control group,while Th2 cell distribution proportion was lower than that of the control group.Conclusion:Conventional anti-infective drugs combined with secretory IgA can further inhibit the inflammatory response and balance the immune response in children with recurrent upper respiratory tract infections.
文摘Recently,new findings have been clarified concerning both pathogenesis and treatment of IgA nephritis.The four hits theory has been confirmed but several genetic wide association studies have allowed finding several genes connected with the pathogenesis of the disease.All these new genes apply to each of the four hits.Additionally,new discoveries concerning the microbiota and its connection with immune system and IgA generation have allowed finding out the role of the mucosa in IgA nephropathy pathogenesis.The IgA treatment is also changed included the future possibilities.The treatment of the chronic kidney disease,associated with the nephropathy,is mandatory,since the beginning of the disease.The classical immunosuppressive agents have poor effect.The corticosteroids remain an important cornerstone in any phase of the disease.More effect is related to the treatment of B cells and plasma cells.In particular,in very recent studies have been documented the efficacy of anti B cell-activating factor and anti A proliferation-inducing ligand agents.Most of these studies are to date in phase II/III.Finally,new agents targeting complement are arising.These agents also are still in randomized trials and act principally in hit 4 where the immunocomplexes in the mesangium activate the different pathways of the complement cascade.
文摘原发性IgA肾病(IgA nephropathy,IgAN)是一种常见的肾小球疾病,是导致肾功能衰竭的重要原因,主要见于青年人和儿童。在过去的几十年里,糖皮质激素疗法一直备受争议。IgA肾病激素治疗评估的全球研究(the therapeutic effects of steroids in IgA nephropathy global,TESTING)始于2012年,是一项国际性、多中心、双盲、随机、安慰剂对照试验,旨在评估在优化支持治疗条件下口服甲泼尼龙治疗进展风险高的IgAN患者的安全性和长期疗效。经过十年的努力,这项研究的成功完成表明,6~9个月的口服甲泼尼龙是保护IgAN高危患者肾功能的有效方案,但也显示出安全问题。TESTING研究发现,与全剂量甲泼尼龙方案相比,减少剂量的甲泼尼龙方案是有益的,且剂量的减少有助于提高甲泼尼龙的使用安全性。总的来说,TESTING研究提供了更多关于IgAN中糖皮质激素治疗剂量和安全性的数据。TESTING研究结果给患有IgAN的患儿提供了重要的启示。随着对IgAN发病机制的深入了解,正在进行的新治疗方案的研究将有助于进一步优化IgAN治疗的获益-风险比。
